EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeit

Difficult-to-treat Takayasu arteritis: a case-based review

Nabil Belfeki, Nouha Ghriss, Renaud Guedec-Ghelfi, Sonia Kammoun, Noemie Abisror, Arsene Mekinian

Rheumatology International · 2024

DOI: 10.1007/s00296-024-05741-y ↗

Kurz gefasst

Fallbericht in der Zeitschrift Rheumatology International, 2024. Verfasst von Nabil Belfeki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Sud Ile de France, Melun, France. nabil.belfeki@ghsif.fr. Hauptthemen laut MEDLINE: Takayasu Arteritis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Takayasu arteritis is a rare chronic inflammatory large vessel vasculitis which affects the aorta and its large branches. The diagnosis is based on the 2022 ACR/EULAR classification criteria for Takayasu arteritis. The management of this vasculitis is challenging. Although it is corticosteroid-responsive, relapses and disease progression are common. Thus, it is possible to resort to alternative conventional synthetic disease-modifying anti-rheumatic drugs and biologics, as second-line such as tumor necrosis factor-alpha inhibitors, tocilizumab, or JAK inhibitors as second-line agents is possible. Nevertheless, in some complex cases, the vasculitis remains active despite different proposed therapeutic lines, and a multitarget approach could induce sustained remission. We report herewith a case of 33-female patient with a refractory Takayasu arteritis which remained active after three different therapeutic lines with tocilizumab, then infliximab, then Upadacitinib. Finally, we consider a successful multitarget approach with a combination of infliximab, Upadacitinib, and methotrexate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Takayasu ArteritisAntibodies, Monoclonal, HumanizedHumansFemaleAdultInfliximabMethotrexateAntirheumatic AgentsDrug Therapy, CombinationTreatment Outcome

Stichwörter der Autor:innen

Biological therapyJanus kinase inhibitorsManagementTakayasu arteritisTocilizumabTumor necrosis factor inhibitors

Substanzen

tocilizumabAntibodies, Monoclonal, HumanizedInfliximabMethotrexateAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Sud Ile de France, Melun, France. nabil.belfeki@ghsif.fr.
  • Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Sud Ile de France, Melun, France.
  • EVESIO Department of Nuclear Medicine, Melun, France.
  • Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy, Assistance Publique - Hôpitaux de Paris, Hôpital Saint-Antoine Paris, Paris, France.
  • Sorbonne University, UMPC University Paris 06, INSERM U938, Centre de Recherche Saint-Antoine (CRSA), Paris, France.

Zitieren

APA

Belfeki, N., Ghriss, N., Guedec-Ghelfi, R., Kammoun, S., Abisror, N., & Mekinian, A. (2024). Difficult-to-treat Takayasu arteritis: a case-based review. Rheumatology International. https://doi.org/10.1007/s00296-024-05741-y

Vancouver

Belfeki N, Ghriss N, Guedec-Ghelfi R, Kammoun S, Abisror N, Mekinian A. Difficult-to-treat Takayasu arteritis: a case-based review. Rheumatology International. 2024. doi:10.1007/s00296-024-05741-y

BibTeX
@article{Belfeki2024,
  author = {Belfeki, Nabil and Ghriss, Nouha and Guedec-Ghelfi, Renaud and Kammoun, Sonia and Abisror, Noemie and Mekinian, Arsene},
  title = {Difficult-to-treat Takayasu arteritis: a case-based review},
  journal = {Rheumatology International},
  year = {2024},
  doi = {10.1007/s00296-024-05741-y}
}
Kostenlos starten →